This week’s newsletter covers California’s cannabis tax debt crisis, social media censorship of cannabis businesses, DoorDash’s entry into hemp product delivery, and a range of new research on CBD, endocannabinoids, and caryophyllene.
Noteworthy Read
California Cannabis Industry Faces Massive Debt (SFGATE)
California’s cannabis industry is struggling under the weight of unpaid taxes, with more than $1.3 billion owed by cannabis operators. Experts warn that the financial strain could lead to widespread closures and jeopardize the future of legal cannabis in the state.
More Noteworthy Reading
Cannabis Operators Report Instagram Page ‘Shadow Bans’ & Closures (MJBizDaily)
Cannabis businesses are increasingly reporting issues with Instagram, including shadow bans and account closures, hindering their ability to market and engage with consumers on the popular platform.
DoorDash Reportedly Now Offering Hemp-Derived THC and CBD Product Deliveries (Ganjapreneur)
DoorDash has reportedly started delivering hemp-derived THC and CBD products, drawing more attention to the glaring issue of hemp’s definition under the current Farm Bill.
Research Round-Up
Efficacy of CBD in the Treatment of Alzheimer’s Disease (Revista FT)
A critical review examines the evidence supporting CBD’s potential in treating Alzheimer’s disease, highlighting its neuroprotective and anti-inflammatory effects.
CBD Effects on Stem Cells (Biofactors)
A study explores how CBD influences stem cell activity, revealing its potential to support cell regeneration and repair, with possible implications for regenerative medicine.
Endocannabinoids & Atherosclerosis (Cardiology Plus)
This review discusses the role of endocannabinoids in cardiovascular health, particularly their potential for developing new treatments to manage and prevent atherosclerosis.
Read more
View more in Endocannabinoid System
Research & Clinical Practice Involving CBD (MDPI)
A comprehensive review of recent studies on CBD highlights its therapeutic applications, including in epilepsy, anxiety, and inflammation, while addressing gaps in research and clinical practice.
Caryophyllene: The Crossover Terpene (CannaMD)
Caryophyllene, a terpene with cannabinoid-like properties, offers therapeutic benefits such as anti-inflammatory and pain-relief effects, making it a unique compound in cannabis research.
Read more
View more in Endocannabinoid System
A heartfelt thank you to all of the CBD brands whose generous support fuels Project CBD’s mission to bring you the latest in plant medicine research and cannabis journalism — we couldn’t do it without you.
